Immune system clues may let some breast cancer patients skip harsh chemo

NCT ID NCT07074106

First seen Apr 04, 2026 · Last updated May 07, 2026 · Updated 6 times

Summary

This study tests a personalized, lighter chemotherapy approach for women with early-stage triple-negative breast cancer. The treatment plan is adjusted based on immune system activity in the tumor and how the tumor shrinks on scans. The goal is to see if many patients can achieve complete cancer disappearance with fewer drugs, avoiding unnecessary side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Instituto D'Or de Pesquisa e Ensino de Brasília

    RECRUITING

    Brasília, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto D'Or de Pesquisa e Ensino de Curitiba

    NOT_YET_RECRUITING

    Curitiba, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto D'Or de Pesquisa e Ensino de Salvador

    RECRUITING

    Salvador, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto D'Or de Pesquisa e Ensino de São Paulo

    RECRUITING

    São Paulo, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro

    RECRUITING

    Rio de Janeiro, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.